Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 3, 2013, Pages 416-423

  Goupil, Rémi ^a   Brachemi, Soumeya ^b   Nadeau, Annie Claire Fredette ^a   Déziel, Clément ^a   Troyanov, Yves ^a   Lavergne, Valery ^a   Troyanov, Stéphan ^a  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; AZATHIOPRINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PLASMAPHERESIS; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CHI-SQUARE DISTRIBUTION; COMMUNICABLE DISEASES; CYCLOPHOSPHAMIDE; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; LYMPHOCYTE COUNT; LYMPHOPENIA; MALE; METHOTREXATE; METHYLPREDNISOLONE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPENIA; PLASMAPHERESIS; QUEBEC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875024174     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07300712     Document Type: Article

References (38)

1. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, Jayne DR, Gaskin G, Rasmussen N, Noë l LH, Ferrario F, Waldherr R, Hagen EC, Bruijn JA, Bajema IM: Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 17: 2264-2274, 2006
2. Weidner S, Geuss S, Hafezi-Rachti S, Wonka A, Rupprecht HD: ANCA-associated vasculitis with renal involvement: An outcome analysis. Nephrol Dial Transplant 19: 1403-1411, 2004
3. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, Plaisance M, Pusey CD, JayneDRW; Pan-Thames Renal Research Group: Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study. Am J Kidney Dis 41: 776-784, 2003
4. Helin K, Honkanen E, Metsaniitty J, Tornroth T: A case of membranous glomerulonephritis associated with adenocarcinoma of pancreas. Nephrol Dial Transplant 13: 1049-1050, 1998
5. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS: Wegener granulomatosis: An analysis of 158 patients. Ann Intern Med 116: 488-498, 1992
6. Charlier C, Henegar C, Launay O, Pagnoux C, Berezné A, Bienvenu B, Cohen P, Mouthon L, Guillevin L: Risk factors for major infections in Wegener granulomatosis: Analysis of 113 patients. Ann Rheum Dis 68: 658-663, 2009
7. Turnbull J, Harper L: Adverse effects of therapy for ANCAassociated vasculitis. Best Pract Res Clin Rheumatol 23: 391-401, 2009
8. Harper L, Savage CO: ANCA-associated renal vasculitis at the end of the twentieth century-a disease of older patients. Rheumatology (Oxford) 44: 495-501, 2005
9. Cohen J, Pinching AJ, Rees AJ, Peters DK: Infection and immunosuppression. A study of the infective complications of 75 patients with immunologically-mediated disease. Q J Med 51: 1-15, 1982
10. Fauci AS, Haynes BF, Katz P, Wolff SM: Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 98: 76-85, 1983
11. Goupil R, Nadeau-Fredette A, Brachemi S, Troyanov S: Severe lymphopenia is frequent and predictive of infectious complications in ANCA vasculitis. Presented at the 2010 Renal Week, Denver, CO, November 16-21, 2010
12. Watts R, Lane S, Hanslik T, Hauser T, Hellmich B, KoldingsnesW, Mahr A, Segelmark M, Cohen-Tervaert JW, Scott D: Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66: 222-227, 2007
13. Luqmani RA, Bacon PA, Moots RJ, Janssen BA, Pall A, Emery P, Savage C, AduD: BirminghamVasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 87: 671-678, 1994
14. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R; European Vasculitis Study Group: EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68: 310-317, 2009
15. Coates TD: Overview of neutropenia. Available at: http://www. uptodate.com. Accessed July 1, 2012
16. Einsele H, Ehninger G, Steidle M, Fischer I, Bihler S, Gerneth F, Vallbracht A, SchmidtH, WallerHD, MüllerCA: Lymphocytopenia as an unfavorable prognostic factor in patients with cytomegalovirus infection after bone marrow transplantation. Blood 82: 1672-1678, 1993
17. Crippa F, Corey L, Chuang EL, Sale G, Boeckh M: Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stemcell transplantation. Clin InfectDis 32: 214-219, 2001
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461-470, 1999
19. McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH: Glucocorticoids and relapse and infection rates in antineutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 7: 240-247, 2012
20. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Nachman PH: Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 143: 621-631, 2005
21. Frome EL: The analysis of rates using Poisson regression models. Biometrics 39: 665-674, 1983
22. Motulsky H: Intuitive Biostatistics. New York, Oxford University Press, 1995
23. Morton M, Edmonds S, Doherty AM, Dhaygude A, Helbert M, Venning M: Factors associated with major infections in patients with granulomatosis with polyangiitis and systemic lupus erythematosus treated for deep organ involvement [published online ahead of print November 2, 2011]. Rheumatol Int doi: 10.1007/s00296-011-2151-0
24. Weidanz F, Day CJ, Hewins P, Savage CO, Harper L: Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kidney Dis 50: 36-46, 2007
25. Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, Tesar V, Vanhille P, Groot KD, Luqmani R, Flores-Suarez LF, Watts R, Pusey C, Bruchfeld A, Rasmussen N, Blockmans D, Savage CO, Jayne D; EUVAS investigators: Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: Long-term follow-up. Ann Rheum Dis 71: 955-960, 2011
26. Glück T, Kiefmann B, Grohmann M, Falk W, Straub RH, Schölmerich J: Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol 32: 1473-1480, 2005
27. Cronstein BN, Naime D, Ostad E: The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 92: 2675-2682, 1993
28. Fauci AS, Dale DC, Wolff SM: Cyclophosphamide and lymphocyte subpopulations in Wegener's granulomatosis. Arthritis Rheum 17: 355-361, 1974
29. Zhu LP, Cupps TR, Whalen G, Fauci AS: Selective effects of cyclophosphamide therapy on activation, proliferation, and differentiation of human B cells. J Clin Invest 79: 1082-1090, 1987
30. Holbro A, Schuetz P, Berger C, Hess C, Daikeler T: Lymphocyte counts in patients with ANCA-associated vasculitis. Rheumatol Int 29: 807-810, 2009
31. Villa-Forte A, Clark TM, Gomes M, Carey J, Mascha E, KarafaMT, Roberson G, Langford CA, Hoffman GS: Substitution of methotrexate for cyclophosphamide in Wegener granulomatosis: a 12-year single-practice experience. Medicine (Baltimore) 86: 269-277, 2007
32. Izzedine H, Cacoub P, Launay-Vacher V, Bagnis C, Deray G: Lymphopenia in Wegener's granulomatosis. A new clinical activity index? Nephron 92: 466-471, 2002
33. Heffernan DS, Monaghan SF, Thakkar RK, Machan JT, Cioffi WG, Ayala A: Failure to normalize lymphopenia following trauma is associated with increased mortality, independent of the leukocytosis pattern. Crit Care 16: R12, 2012
34. El SaleebyCM, SomesGW, DeVincenzo JP, GaurAH: Risk factors for severe respiratory syncytial virus disease in children with cancer: The importance of lymphopenia and young age. Pediatrics 121: 235-243, 2008
35. Aberg JA, Kaplan JE, Libman H, Emmanuel P, Anderson JR, Stone VE, Oleske JM, Currier JS, Gallant JE; HIV Medicine Association of the Infectious Diseases Society of America: Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 49: 651-681, 2009
36. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl JMed 363: 211-220, 2010
37. KDIGO Clinical Practice Guideline for Glomerulonephritis: Kidney Int Suppl 2: s140-s274, 2012
38. Viscoli C, Varnier O, Machetti M: Infections in patients with febrile neutropenia: Epidemiology, microbiology, and risk stratification. Clin Infect Dis 40[Suppl 4]: S240-S245, 2005